To include your compound in the COVID-19 Resource Center, submit it here.

Synbal: Gene driving on parallel tracks

How Synbal is gene-driving to new rodent models, rare disease cell therapies

Synbal is tapping new genetic approaches to develop both rodents with humanized metabolisms and cell therapies for lysosomal storage diseases.

Ethan Bier, Valentino Gantz and Tsvi Goldenberg spun out Synbal Inc. from the University of California San Diego in 2015 based on tech Bier and Gantz reported in two papers that year: one in Science demonstrating a single-step CRISPR-based gene drive system propagated homozygous changes in a population

Read the full 679 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers